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Background: PET/CT scans acquired in the radiotherapy treatment position are typically performed without
compensating for respiratory motion. The purpose of this study was to investigate geographic miss of lung
tumours due to respiratory motion for target volumes defined on a standard 3D-PET/CT.
Methods: 29 patients staged for pulmonary malignancy who completed both a 3D-PET/CT and 4D-PET/CT were
included. A 3D-Gross Tumour Volume (GTV) was defined on the standard whole body PET/CT scan. Subsequently a
4D-GTV was defined on a 4D-PET/CT MIP. A 5 mm, 10 mm, 15 mm symmetrical and 15?10 mm asymmetrical
Planning Target Volume (PTV) was created by expanding the 3D-GTV and 4D-GTV ? s. A 3D conformal plan was
generated and calculated to cover the 3D-PTV. The 3D plan was transferred to the 4D-PTV and analysed for geographic
miss. Three types of miss were measured. Type 1: any part of the 4D-GTV outside the 3D-PTV. Type 2: any part of the
4D-PTV outside the 3D-PTV. Type 3: any part of the 4D-PTV receiving less than 95% of the prescribed dose. The lesion
motion was measured to look at the association between lesion motion and geographic miss.
Results: When a standard 15 mm or asymmetrical PTV margin was used there were 1/29 (3%) Type 1 misses. This
increased 7/29 (24%) for the 10 mm margin and 23/29 (79%) for a 5 mm margin. All patients for all margins had a
Type 2 geographic miss. There was a Type 3 miss in 25 out of 29 cases in the 5, 10, and 15 mm PTV margin groups.
The asymmetrical margin had one additional Type 3 miss. Pearson analysis showed a correlation (p < 0.01) between
lesion motion and the severity of the different types of geographic miss.
Conclusion: Without any form of motion suppression, the current standard of a 3D- PET/CT and 15 mm PTV margin
employed for lung lesions has an increasing risk of significant geographic miss when tumour motion increases. Use of
smaller asymmetric margins in the cranio-caudal direction does not comprise tumour coverage. Reducing PTV margins
for volumes defined on 3D-PET/CT will greatly increase the chance and severity of a geometric miss due to respiratory
motion. 4D-imaging reduces the risk of geographic miss across the population of tumour sizes and magnitude of
motion investigated in the study.
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The use of integrated PET/CT in establishing radiotherapy
target volumes is becoming increasingly accepted as the
optimal approach for many malignancies, in particular
lung cancer [1,2]. When defining target volumes for lung
cancer the information obtained from the two imaging
modalities provides complementary information about
both tumour morphology (CT) and physiology (PET) [3].
This allows optimal definition of the tumour with good re-
producibility while sparing delivery of dose to normal or-
gans [4,5]. However a lung tumour can exhibit significant
respiratory motion due to normal breathing, thus increas-
ing the risk of geographic miss [6,7]. Therefore, target vol-
umes need to be defined in order to minimize the
potential of geographic miss during respiratory motion.
In many centres, PET/CT scans acquired in the radio-
therapy treatment position is typically performed without
compensating for the effects of respiratory motion. Areas
most affected by respiratory motion are the lungs, liver
and upper abdomen, particularly for structures close to
the diaphragm. The standard method to account for mo-
tion is to apply a large margin to the gross tumour volume
(GTV) to ensure adequate tumour coverage in a one-size
fits all approach. However, a number of studies have found
that target volumes are underestimated on a standard 3D-
PET/CT scan when compared to target volumes defined
on respiratory gated or 4D imaging [8-10]. This is primar-
ily due to the effect of respiratory motion leading to count
averaging across voxels through which the lesion moves
or in which it resides for a relatively short period of the re-
spiratory cycle.
When respiratory motion is taken into account the
most common approach is to acquire a 4D-CT scan and
this has become a routine clinical tool in some centres
[11-13]. A recent study has found that adding a 4D-PET
to a 4D-CT scan alters target volumes for lung tumours
in approximately 23% of cases [14]. This would indicate
that it may be important to incorporate both 4D-PET
and 4D-CT information into the planning process.
The purpose of this study was therefore to investigate
geographic miss of lung tumours due to respiratory mo-
tion for target volumes defined on a standard 3D-PET/CT
scan when compared to target volumes defined on a 4D-
PET/CT scan, assuming that the tumour should reside
within the target volume for 100% of radiation delivery. In
addition, we assessed the potential of applying individua-
lised margins by exploring the degree of geographic miss
when different margins are applied to the target volume to
investigate the potential of individualised margins.
Methods
Patients
A total of 29 consecutive patients with staged for pulmon-
ary malignancy who had completed both a 3D-PET/CTand 4D-PET/CT contemporaneously between August 2011
and May 2012. All patients gave their informed consent to
participate in a study. Patients were included if they had
an 18 F-fluoro-2′-deoxy-d-glucose (FDG) avid lung nodule
with an SUV greater than 2.0 and larger than 15 mm in
smallest diameter. These levels were chosen to minimise
the effects of partial voluming and to ensure that the le-
sion could be resolved on the PET scan. This study was
approved by the Clinical Research and Ethics Committee
of the Peter MacCallum Cancer Centre.
Scanning protocol
All patients were scanned on a GE Discovery 690 (GE
Medical Systems Milwaukee, WI). The patients were
scanned using the same acquisition protocol outlined in
our previous work validating a 4D-PET maximum inten-
sity projection (MIP) for target volume delineation [8].
The protocol involves first acquiring a standard whole-
body PET/CT with the patient breathing freely. Then a
single bed step 4D-PET/CT scan centred over the lesion
of interest is immediately acquired after the standard
PET/CT without the patient moving in between scans.
Lesion contouring and planning
Gross Tumour Volume (GTV) definition
The lesion contouring protocol used was based on our
published work that uses information from both the PET
and CT scans to define the GTV [4]. All lung lesions were
contoured by a single radiation oncologist experienced
with this protocol. First, a 3D-GTV was defined on the
standard whole-body PET/CT scan. Then a 4D-GTV was
defined by the same observer on a 4D-PET/CT MIP. The
4D-PET/CT MIP consisted of a fused 4D-CT MIP and
4D-PET MIP as outlined in our previous work [8]. All
contouring was performed on MIM Maestro imaging soft-
ware (MIM 5.4.4, MIM Software Inc. Cleveland, OH,
USA).
Planning Target Volume (PTV) definition
Using the MIM contour expansion tool eight PTV ? s were
created, four 3D-PTV contours and four 4D-PTV con-
tours. Firstly, three symmetrical PTV contours were cre-
ated by expanding the 3D-GTV isotropically by 5 mm,
10 mm, and 15 mm. Subsequently, an asymmetrical con-
tour was created by expanding the GTV anisotropically by
15 mm in the superior/inferior (SI) direction and 10 mm
in the axial directions. Finally, these same four PTV ? s
(5 mm, 10 mm, 15 mm and anisotropic) were then created
based on the 4D-GTV. This process is illustrated in
Figure 1.
Treatment planning
All plans were generated on the XiO planning system
(Computerized Medical Systems CMS, St Louis, MO,
Figure 1 The top row shows the four different margin expansions applied to the GTV to create four PTV contours. The bottom row
shows the types of geographic miss as a result of tumour motion due to respiration investigated.
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multileaf collimator (MLC) on a Varian machine. A
2.5 mm grid size was used and a fast superposition algo-
rithm to account for tissue inhomogeneity. Each plan
contained three or four fields arranged according to the
tumour and critical organ location, prescribing 60Gy in
30Fractions consistent with institutional protocols and
ICRU guidelines. All plans were calculated for 95% of
the prescribed dose covered the PTV.
Each case had four plans developed, beginning with the
15 mm FB-PTV. The same beam arrangement was main-
tained for subsequent volumes, FB-10 mm, FB- 5 mm and
Asymmetrical FB-PTV. The MLC arrangement was ad-
justed for the variation in volume size. The plans were
transferred to the corresponding 4D - PTV and dosimetry
was analysed using the dose volume histogram tool.
Measurement of tumour motion
The tumour was first contoured on the 4D-CT scan in
peak expiration phase when the tumour has the least
amount of motion. Then the contour was automatically
propagated across all the 4D-CT phases with deformable
contour propagation [15]. The contours were manually
checked for any gross errors introduced by the automatic
process. This process copied a contour from one image to
the next and applied a deformation to the contour to ac-
count for movement of an object. The motion of thetumour was measured by recording the distance the cen-
troid position of the contour moved in the SI plane.
After contouring the patients were placed into 4 motion
groups based on the amount of motion in the superior/in-
ferior (SI) plane. The motion groups used were; < 5 mm,
≤ 10 mm, 10 ≤ 20 mm and greater than 20 mm. The
tumour size was automatically measured in the superior/in-
ferior plane by MIM. The ratio of the lesion motion to
tumour size was then investigated for correlation between
motion and miss. For example a 20 mm lesion that moved
20 mm would have a motion to size ratio of 1.0. If a 40 mm
lesion motion moved 20 mm the ratio would be 0.5. This
parameter takes into account both tumour size and motion.
Analysis of geographic miss
Our previously published criteria were adapted to inves-
tigate geographic miss in 3D vs 4D defined target vol-
umes [16]. 4D-PET/CT has been shown to account well
for tumour motion it was considered the reference for
which the 3D-PET/CT was compared against [17-19].
The types of geographic miss were defined as follows
and are outlined in Figure 1.
 Type 1 miss ? Any part of the 4D-GTV outside the
3D-PTV,
 Type 2 miss ? Any part of the 4D-PTV outside the
3D-PTV,
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less than 95% of the prescribed dose (where
planning was based on the 3D-PTV).
The Type 3 miss was further divided into four groups:
 No Type 3 miss ? 100% 4D-PTV receiving 95% of
the prescribed dose,
 Minor Type 3 miss ? >95% of 4D-PTV receiving
95% prescribed dose,
 Moderate Type 3 miss ? 90-95% OF 4D-PTV
receiving 95% prescribed dose,
 Significant Type 3 miss ? <90% of the 4D-PTV
receiving 95% prescribed dose.
Data analysis
All statistical tests were carried out using GraphPad
Prism 5 (GraphPad Software, LaJolla, Ca). The mean
(?SD) 3D and 4D volumes were compared and tested
for difference using a paired students ? t-test. For each
type of miss the mean (?SD) volume that was missed
was calculated. A chi-squared test was used to determine
if there was a difference in the proportion of patients
with a miss between the different PTV margin groups.
Pearson ? s correlation coefficients were used to examine
the association between lesion motion and the volume
of geographic miss as well as the ratio of size to motion




29 patients were included in the study with a mean age
of 68 (range 45 ? 87), 18 (62%) patients were male and 11
(38%) were female. A comparison of the 3D and 4D vol-
umes is shown in Table 1. The 4D-GTV was on average
50% (range 2%-446%) larger than the 3D-GTV (p < 0.01).
In turn the 4D-PTV ? s were larger than the 3D-PTV ? s
across all margins applied (p < 0.01). The 10 mm 4D-
PTV was on average 19% smaller than the 15 mm 3D-PTV
(p < 0.01).Table 1 A comparison of mean 3D-PET/CT defined
volumes to 4D-PET/CT defined volumes (total n = 29)
3D volume 4D volume
(ml) (ml) Diff p value
GTV 15.7 23.5 50% 0.0013
PTV 5 mm 38.5 53.9 40% 0.0001
PTV 10 mm 72.8 96.1 32% <0.0001
PTV 15 mm 119.2 155.9 31% <0.0001
Asym 85.5 112.0 31% <0.0001
15 mm vs 10 mm 119.2 96.1 19% <0.0001Type 1 miss - any part of the 4D-GTV outside the 3D-PTV
The proportions of patients with a Type 1 miss are
shown in Figure 2a. When a standard 15 mm or asym-
metrical PTV margin was used there was only one case
of Type 1 miss in the group with the highest range of le-
sion motion. There was a significant difference in the
proportion of patients with a Type 1 miss between the
symmetrical PTV groups (15 mm vs 10 mm; p = 0.02,
10 mm vs 5 mm; chi-squared test, p < 0.01). There was
no difference between the standard 15 mm PTV group
and the asymmetrical PTV group.
As the lesion motion in the superior/inferior plane in-
creased the proportion of patients with a Type 1 miss in-
creased across all PTV margins (Figure 2a). Additionally,
as the motion increased the percentage volume of the
4D-GTV that was missed by the 3D-PTV increased
across all margins (Table 2b). An example of a patient
with a type 1 miss using all four PTV margins is shown
in Figure 3.
Type 2 miss - any part of the 4D-PTV outside the 3D-PTV
All patients for all PTV margins had a Type 2 geo-
graphic miss. The mean percentage of the 4D-PTV that
was missed by the 3D-PTV is outlined in Figure 2c. A
Pearson correlation showed a significant correlation (p
< 0.01) between lesion motion and the amount of the
4D-PTV that was missed by the 3D-PTV across all PTV
margins (15 mm r = 0.61, 10 mm r = 0.60, 5 mm r = 0.53,
asym r = 0.60). A stronger correlation was found when the
motion to lesion size ratio was used (15 mm r = 0.67,
10 mm r = 0.66, 5 mm r = 0.65, asym r = 0.68).
Type 3 miss - any part of the 4D-PTV receiving less than
95% of the prescribed dose (where planning was based on
the 3D-PTV)
There was a Type 3 miss in 25 out of 29 cases in the 5,
10, and 15 mm PTV margin groups. The asymmetrical
margin had one additional Type 3 miss. The mean
coverage of the 4D-PTV by the 3D-PTV plan is outlined
in Figure 2d. A Pearson correlation showed an associ-
ation (p < 0.01) between lesion motion and the percent-
age of the 4D-PTV that was missed by the 3D-PTV with
all PTV margins (15 mm r = 0.57, 10 mm r = 0.54, 5 mm
r = 0.57, asym r = 0.47). A stronger correlation was found
when the motion to lesion size ratio was used (15 mm
r = 0.61, 10 mm r = 0.60, 5 mm r = 0.64, asym r = 0.57).
An example of a patient with a significant Type 3 miss is
shown in Figure 4.
Table 2 outlines the data for the severity of the Type 3
miss based on the average 4D-PTV coverage. On average
if there was less than 5 mm of motion any miss was
minor (< 5%) and not likely to be clinically significant.
When there was a high range of lesion motion (> 20 mm)
the average target volume coverage resulted in a significant
Figure 2 Summary of results for the three types of geographic miss. a: The proportions of patients with a type 1 miss in the four motion
groups using the different PTV margins. b: The mean % of the 4D-GTV that was missed by the 3D-PTV when there was a type 1 miss. c: The mean % of
the 4D-PTV that was missed by the 3D-PTV. d: The mean coverage of the 4D-PTV with 95% of the prescribed dose.
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scribed dose in the >20 mm group was; 5 mm = 67%,
10 mm = 76%, 15 mm = 79% and asym = 81%).
Discussion
In this study we compared a standard technique of de-
lineating the GTV on a 3D-PET/CT to an improved
technique of 4D-PET/CT. Our work has found that 3D-
PET/CT defined target volumes underestimate the true
extent of respiratory motion despite being considered aTable 2 Type 3 miss: the severity of the Type 3 geographic mis











0- < 5 mm (n = 8) Minor 97 [2.9] Minor 97 [1.7
5- < 10 mm (n = 6) Moderate 93 [5.9] Moderate 95 [7.9
10- < 20 mm (n = 11) Significant 86 [8.8] Moderate 92 [5.3
20+ mm (n = 4) Significant 67 [16.7] Significant 76 [10? slow ? imaging modality that combines imaging informa-
tion from all phases of the breathing cycle. This under-
estimation of the tumour motion led to increasingly
severe geographic miss as the tumour motion increased.
This is consistent with other studies comparing 3D and
4D-PET/CT volumes [8,9,18].
Results of this study also revealed that the ratio of le-
sion size to the amount of motion also appears to impact
the severity of geographic miss. For example a small le-















] Minor 98 [3.3] Minor 98 [4.2]
] Moderate 95 [4.8] Minor 95 [5.4]
] Moderate 92 [4.4] Moderate 92 [3.9]
.9] Significant 79 [12.0] Significant 81 [14.0]
Figure 3 CT scan of a patient with a small lower lobe tumour. The 4D-GTV is shown in red and the 3D-PTV is shown in green. The highlighted
red area is the part of the 4D-GTV that was not covered by the 3D-PTV for the margin applied.
Figure 4 A CT scan of a patient with a small lower lobe tumour.
The 4D-PTV is shown in red and the green area show the 95% isodose
line. The solid red area is the part of the 4D-PTV that would not receive
the prescribed dose and constitutes a Type 3 geographic miss.
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across the same distance.
It has been possible for some time to perform both a
4D CT and a 4D PET scan in the same session on a
PET/CT scanner [20]. While the technology has ad-
vanced and become more widely available it is still not
commonly applied. One reason for this may be due to
the limited number of studies showing clinical benefit
that would compensate for the additional resources re-
quired to complete a 4D-PET/CT scan. The main reason
to acquire a 4D scan to define target volumes is to min-
imise the risk of a geographic miss, thereby increasing
the probability of attaining tumour control and en-
hanced patient outcomes. Sura and colleagues (2008)
studied patterns of local failure in 34 lung lesions in 26
patients. They found that for a lung tumour receiving
more than 60Gy the site of failure was mostly at the
margins of the GTV [21]. As 3D-PET/CT can underesti-
mate target volumes a possible explanation for the ob-
served local failures is tumour motion due to normal
respiration. A lung tumour that moves out of a defined
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missed, thereby increasing the risk of local failure.
Not surprisingly, these data show that the severity of
the geographic miss rises significantly when a PTV mar-
gin is reduced from the standard 15 mm. This further
confirms our institutional practice of using at least a
15 mm margin if there is no motion management in
place. When employing highly conformal techniques
such as stereotactic body radiotherapy (SABR) it is com-
mon to add only 5 mm margins to the GTV. If only a
3D-PET/CT scan or 3D-CT alone is used to delineate a
GTV for stereotactic treatment these data suggests that
there is a high likelihood of a significant geographic
miss. The planning techniques are different in SABR
with sharper dose gradients at the edge of the PTV and
this may lead to and even more significant miss than de-
scribed in this work.
In the delivery of radiation therapy to lung tumours
there is always a need to reduce the dose to normal lung
in order to minimise pulmonary toxicity. 4D-PET/CT
imaging is not widely available so many centres may not
be able to use this technique. Therefore in this study we
compared geographic miss of a standard 15 mm margin
to a 15x10mm asymmetrical margin. In this study rates
of geographic miss were similar for symmetrical and
asymmetrical margins. This was because most of the
tumour motion occurs in the SI plane and reducing the
margins in the other planes does not greatly increase
the risk of a geographic miss. Using an asymmetric
PTV margin is a method that could be employed on a
3D-PET/CT scan to reduce lung dose however further
work in a larger cohort is warranted.
In most patients, if a 15 mm margin is applied to a
4D-GTV the resultant 4D-PTV will be significantly lar-
ger than a 3D-PTV, thereby potentially increasing normal
lung dose. Conventional GTV to PTV margins allow for
motion and set-up uncertainties. Assuming that the mag-
nitude of both these uncertainties is similar and independ-
ent of each other our original margin of 15 mm on the
3D-GTV could be reduced. The use of 4D imaging pro-
vides not only the magnitude of motion but also defines
the centre location more accurately than 3D scanning. We
feel a margin reduction to 10 mm is justified in cases
where motion has been accounted for in the GTV. As
Table 1 shows this has the potential to reduce the actual
irradiated volume significantly. The mean 4D-GTV with a
10 mm margin was 96.1 ml, which was significantly
smaller than a 3D-GTV with a 15 mm margin (119.2 ml).
However, individual radiotherapy departments would need
to adjust safety margins individualised to department spe-
cific equipment and processes.
4D target volumes provide potential to customise a pa-
tients target volume and resultant radiotherapy plan
based on their individual tumour motion [16]. What weand other authors have established that tumour motion
is highly variable between patients and can be visualised
using 4D scanning [22,23]. As it is becoming common
practice to use a PET/CT in the planning process it would
be an efficient use of resources to add a 4D-PET/CT at
this time point. Depending on the amount of tumour mo-
tion observed a target volume could be tailored to suit
their individual lesion trajectory. This will either ensure
correct tumour coverage for a highly mobile tumour or
allow normal tissue dose reduction in fixed tumours. Con-
versely these data show that if a radiotherapy department
does not have any motion management equipment with
their PET/CT scanner then they should not attempt to re-
duce safety margins from the larger 15 mm expansion.
Further work investigating personalising target volumes is
warranted and may improve local tumour control or re-
duce risks of side effects.
Based on our retrospective study there is no way to
know if the types of geographic miss measured trans-
lated to decreases in tumour control. However it is
known that the radiation dose to a tumour is a good
predictor for local control (18, 19). Also a geographic
miss such as described in this study would constitute a
protocol violation and as was shown by Peters et al. ad-
herence to protocol is a good predictor of overall sur-
vival [24]. It is therefore reasonable to infer that any
form of geographic miss would lead to a reduction in
tumour dose and subsequently increase the risk of treat-
ment failure. A 4D-PET/CT scan incorporated into a
planning PET/CT is an achievable method of accurately
establishing and accounting for the adverse effects of re-
spiratory motion on treatment success.Conclusions
Without any form of motion suppression the current
standard of a 3D- PET/CT and 15 mm PTV margin
employed for lung lesions has an increasing risk of sig-
nificant geographic miss in particular when tumour mo-
tion increases. Use of smaller asymmetric margins in the
cranio-caudal direction does not comprise tumour
coverage. Reducing PTV margins for volumes defined
on 3D-PET/CT will greatly increase the chance and se-
verity of a geometric miss due to respiratory motion.
4D-imaging reduces the risk of geographic miss across
the population of tumour sizes and magnitude of motion
investigated in the study.
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